-
1
-
-
0031435837
-
Mechanisms of drug resistance in hematologic malignancies
-
Dalton WS. Mechanisms of drug resistance in hematologic malignancies. Semin Hematol 34: 3-8, 1997.
-
(1997)
Semin Hematol
, vol.34
, pp. 3-8
-
-
Dalton, W.S.1
-
2
-
-
0024360795
-
P-glycoprotein and multidrug resistance in cancer chemotherapy
-
Deuchars KL, Ling V. P-glycoprotein and multidrug resistance in cancer chemotherapy. Semin Oncol 16: 156-165, 1989.
-
(1989)
Semin Oncol
, vol.16
, pp. 156-165
-
-
Deuchars, K.L.1
Ling, V.2
-
3
-
-
0345505691
-
The role of multidrug transporters in drug availability, metabolism and toxicity
-
Bodo A, Bakos E, Szeri F, et al. The role of multidrug transporters in drug availability, metabolism and toxicity. Toxicol Lett 140: 133-143, 2003.
-
(2003)
Toxicol Lett
, vol.140
, pp. 133-143
-
-
Bodo, A.1
Bakos, E.2
Szeri, F.3
-
4
-
-
1142291910
-
Drug resistance in breast cancer
-
Lage H. Drug resistance in breast cancer. Cancer Therapy 1: 81-91, 2003.
-
(2003)
Cancer Therapy
, vol.1
, pp. 81-91
-
-
Lage, H.1
-
5
-
-
12944277104
-
A common pharmacophore for epothilone and taxanes: Molecular basis of drug resistance conferred by tubulin mutations in human cancer cells
-
Giannakakau P, Gussio R, Nogales E, et al. A common pharmacophore for epothilone and taxanes: Molecular basis of drug resistance conferred by tubulin mutations in human cancer cells. Proc Nat Acad Sci USA 97: 2904-2909, 2000.
-
(2000)
Proc Nat Acad Sci USA
, vol.97
, pp. 2904-2909
-
-
Giannakakau, P.1
Gussio, R.2
Nogales, E.3
-
6
-
-
0034624329
-
Differential sensitivity of MCF-7 and LCC2 cells, to multiple growth inhibitory agents: Possible relation to high bcl-2/bax ratio?
-
Lilling G, Hacohen H, Nordenberg J, et al. Differential sensitivity of MCF-7 and LCC2 cells, to multiple growth inhibitory agents: Possible relation to high bcl-2/bax ratio? Cancer Lett 161: 27-34, 2000.
-
(2000)
Cancer Lett
, vol.161
, pp. 27-34
-
-
Lilling, G.1
Hacohen, H.2
Nordenberg, J.3
-
7
-
-
0042024879
-
An in vitro study to evaluate the synergistic activity of norfloxacin and metronidazole
-
Bharadwaj R, Vidya A, Dewan B, Pal A. An in vitro study to evaluate the synergistic activity of norfloxacin and metronidazole. Indian J Pharmacol 35: 220-226, 2003.
-
(2003)
Indian J Pharmacol
, vol.35
, pp. 220-226
-
-
Bharadwaj, R.1
Vidya, A.2
Dewan, B.3
Pal, A.4
-
8
-
-
0035197533
-
Combination chemotherapy of the taxanes and antimetabolites: Its use and limitations
-
Smorenburg CH, Sparreboom A, Bontenbal M, Verweij J. Combination chemotherapy of the taxanes and antimetabolites: Its use and limitations. Eur J Cancer 37: 2310-2323, 2001.
-
(2001)
Eur J Cancer
, vol.37
, pp. 2310-2323
-
-
Smorenburg, C.H.1
Sparreboom, A.2
Bontenbal, M.3
Verweij, J.4
-
9
-
-
27644497583
-
Weekly administration of docetaxel and paclitaxel in metastatic or advanced breast cancer
-
Enju A, Palmieri FM, Perez EA. Weekly administration of docetaxel and paclitaxel in metastatic or advanced breast cancer. Oncologist 10: 665-85, 2005.
-
(2005)
Oncologist
, vol.10
, pp. 665-685
-
-
Enju, A.1
Palmieri, F.M.2
Perez, E.A.3
-
10
-
-
0031409092
-
Clinical Oncology Update, Review of recent trials of chemotherapy for advanced breast cancer: The taxanes
-
Clemons M, Leahy M, Valle J, et al. Clinical Oncology Update, Review of recent trials of chemotherapy for advanced breast cancer: The taxanes. Eur J Cancer 33: 2183-93, 1997.
-
(1997)
Eur J Cancer
, vol.33
, pp. 2183-2193
-
-
Clemons, M.1
Leahy, M.2
Valle, J.3
-
11
-
-
0019805521
-
Taxol-induced polymerization of purified tubulin: Mechanism of action
-
Kumar N. Taxol-induced polymerization of purified tubulin: Mechanism of action. J Biol Chem 256: 10435-41,1981.
-
(1981)
J Biol Chem
, vol.256
, pp. 10435-10441
-
-
Kumar, N.1
-
12
-
-
0036634786
-
Survival of docetaxel-resistant prostate cancer cells in vitro depends on phenotype alterations and continuity of drug exposure
-
Makarovskiy AN, Siryaporn E, Hixson DC, Akerley W. Survival of docetaxel-resistant prostate cancer cells in vitro depends on phenotype alterations and continuity of drug exposure. Cell Mol Life Sci 59: 1198-211, 2002.
-
(2002)
Cell Mol Life Sci
, vol.59
, pp. 1198-1211
-
-
Makarovskiy, A.N.1
Siryaporn, E.2
Hixson, D.C.3
Akerley, W.4
-
13
-
-
0029360519
-
Microtubule dynamics: Taking aim at a moving target
-
Wilson L, Jordan MA. Microtubule dynamics: taking aim at a moving target. Chem Biol 2: 569-73, 1995.
-
(1995)
Chem Biol
, vol.2
, pp. 569-573
-
-
Wilson, L.1
Jordan, M.A.2
-
14
-
-
0025272246
-
Topoietoposide, and cytarabine in patients with refractory and relapsed acute myelogenous leukemia (AML)
-
Zijlstra JG, deJong S, deVries EG, Mulder NH. Topoietoposide, and cytarabine in patients with refractory and relapsed acute myelogenous leukemia (AML). Tumor Pharmacother 7: 11-18, 1990.
-
(1990)
Tumor Pharmacother
, vol.7
, pp. 11-18
-
-
Zijlstra, J.G.1
deJong, S.2
deVries, E.G.3
Mulder, N.H.4
-
15
-
-
0025155529
-
Epirubicincardio-toxicity: A studyof 135 patients with advanced breast cancer
-
Nielsen D, Jensen JB, Dombernowsky P. Epirubicincardio-toxicity: A studyof 135 patients with advanced breast cancer. J Clin Oncol 8: 1806-1810, 1990.
-
(1990)
J Clin Oncol
, vol.8
, pp. 1806-1810
-
-
Nielsen, D.1
Jensen, J.B.2
Dombernowsky, P.3
-
16
-
-
0031468368
-
Anthracyclines in haematology: During chemotherapy; preclinical studies, toxicity and delivery systems
-
Richardson DS, Johnson SA. Anthracyclines in haematology: during chemotherapy; preclinical studies, toxicity and delivery systems. Blood Rev 11: 201-223, 1997.
-
(1997)
Blood Rev
, vol.11
, pp. 201-223
-
-
Richardson, D.S.1
Johnson, S.A.2
-
17
-
-
0028234673
-
Up-regulation of a mutant form of p53 by doxorubicin in human squamous carcinoma cells
-
Kwok TT, Mok CH, Menton-Brennan L. Up-regulation of a mutant form of p53 by doxorubicin in human squamous carcinoma cells. Cancer Res 54: 2834-36, 1994.
-
(1994)
Cancer Res
, vol.54
, pp. 2834-2836
-
-
Kwok, T.T.1
Mok, C.H.2
Menton-Brennan, L.3
-
18
-
-
0024312674
-
Tamoxifen therapy in breast cancer: Biology, efficacy, and side effects
-
Love RR. Tamoxifen therapy in breast cancer: biology, efficacy, and side effects. J Clin Oncol 7: 803-15, 1989.
-
(1989)
J Clin Oncol
, vol.7
, pp. 803-815
-
-
Love, R.R.1
-
19
-
-
0030764346
-
Inhibition of trans-retinoic acid-resistant human breast cancer cell growth by retinoid X receptor-selective retinoids
-
Wu Q, Dawson MI, Zheng Y, et al. Inhibition of trans-retinoic acid-resistant human breast cancer cell growth by retinoid X receptor-selective retinoids. Mol Cell Biol 17: 6598-608, 1997.
-
(1997)
Mol Cell Biol
, vol.17
, pp. 6598-6608
-
-
Wu, Q.1
Dawson, M.I.2
Zheng, Y.3
-
20
-
-
33845936497
-
Development of Rational in-vitro Models for Drug Resistance in Breast Cancer and Modulation of MDR by Selected Compounds
-
Kars MD, Iseri ÖD, Gündüz U, et al. Development of Rational in-vitro Models for Drug Resistance in Breast Cancer and Modulation of MDR by Selected Compounds. Anticancer Res 26: 4559-68, 2006.
-
(2006)
Anticancer Res
, vol.26
, pp. 4559-4568
-
-
Kars, M.D.1
Iseri, O.D.I.E.D.2
Gündüz, U.3
-
21
-
-
37549029516
-
In Vitro evaluation of zoledronic acid resistance developed in MCF-7 cells
-
Kars MD, Iseri ÖD, Ural AU, Gündüz U. In Vitro evaluation of zoledronic acid resistance developed in MCF-7 cells. Anticancer Res 27: 4031-38, 2007.
-
(2007)
Anticancer Res
, vol.27
, pp. 4031-4038
-
-
Kars, M.D.1
Iseri, O.D.I.E.D.2
Ural, A.U.3
Gündüz, U.4
-
22
-
-
0002515716
-
Antimicrobial combinations
-
Lorian V, eds, USA, Williams and Wilkins
-
Eliopoulos GM, Moellering JR RC. Antimicrobial combinations. In: Lorian V, eds. Antibiotics in Laboratory Medicine. USA, Williams and Wilkins. 1980, pp 432-443.
-
(1980)
Antibiotics in Laboratory Medicine
, pp. 432-443
-
-
Eliopoulos, G.M.1
Moellering, J.R.2
-
23
-
-
0344678381
-
Current options in treatment of anthracycline-resistant breast cancer
-
Kröger N, Achterrath W, Hegewisch-Becker S, et al. Current options in treatment of anthracycline-resistant breast cancer. Cancer Treat Rev 25: 279-291, 1999.
-
(1999)
Cancer Treat Rev
, vol.25
, pp. 279-291
-
-
Kröger, N.1
Achterrath, W.2
Hegewisch-Becker, S.3
-
24
-
-
21044456009
-
Efficacy of weekly paclitaxel in patients with docetaxel-resistant metastatic breast cancer
-
Yonemori K, Katsumata N, Uno H, et al. Efficacy of weekly paclitaxel in patients with docetaxel-resistant metastatic breast cancer. Breast Cancer Res Tr 89: 237-241, 2005.
-
(2005)
Breast Cancer Res Tr
, vol.89
, pp. 237-241
-
-
Yonemori, K.1
Katsumata, N.2
Uno, H.3
-
25
-
-
1842554867
-
Cross-resistance studies of isogenic drug-resistant breast tumor cell lines support recent clinical evidence suggesting that sensitivity to paclitaxel may be strongly compromised by prior doxorubicin exposure
-
Guo B, Villeneuve DJ, Hembruff SL, et al. Cross-resistance studies of isogenic drug-resistant breast tumor cell lines support recent clinical evidence suggesting that sensitivity to paclitaxel may be strongly compromised by prior doxorubicin exposure. Breast Cancer Res Tr 85: 31-51, 2004.
-
(2004)
Breast Cancer Res Tr
, vol.85
, pp. 31-51
-
-
Guo, B.1
Villeneuve, D.J.2
Hembruff, S.L.3
-
26
-
-
0031441798
-
Prospects with docetaxel in the treatment of patients with breast cancer
-
Marty M, Extra JM, Cottu PH, Espie M. Prospects with docetaxel in the treatment of patients with breast cancer. Eur J Cancer 33: 26-29, 1997.
-
(1997)
Eur J Cancer
, vol.33
, pp. 26-29
-
-
Marty, M.1
Extra, J.M.2
Cottu, P.H.3
Espie, M.4
-
27
-
-
35748948098
-
Overview and new strategies in metastatic breast cancer (MBC) for treatment of tamoxifen-resistant patients
-
Adamo V, Iorfida M, Montalto E, et al. Overview and new strategies in metastatic breast cancer (MBC) for treatment of tamoxifen-resistant patients. Ann Oncol 18: 53-57, 2007.
-
(2007)
Ann Oncol
, vol.18
, pp. 53-57
-
-
Adamo, V.1
Iorfida, M.2
Montalto, E.3
-
28
-
-
0031758794
-
A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer
-
Valero V, Jones SE, Von Hoff DD, et al. A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. J Clin Oncol 16: 3362-8, 1998.
-
(1998)
J Clin Oncol
, vol.16
, pp. 3362-3368
-
-
Valero, V.1
Jones, S.E.2
Von Hoff, D.D.3
-
29
-
-
0037141341
-
Expression of multidrug resistance-associated protein1, Pglycoprotein, and thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection
-
Choi H, Lim H-Y, Joo HJ, et al. Expression of multidrug resistance-associated protein1, Pglycoprotein, and thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection. Brit J Cancer 86: 1578-85, 2002.
-
(2002)
Brit J Cancer
, vol.86
, pp. 1578-1585
-
-
Choi, H.1
Lim, H.-Y.2
Joo, H.J.3
-
30
-
-
0025821275
-
Multidrug-resistant myeloma: Laboratory and clinical effects of verapamil as a chemosensitizer
-
Salmon SE, Dalton WS, Grogan TM, et al. Multidrug-resistant myeloma: Laboratory and clinical effects of verapamil as a chemosensitizer. Blood l78: 44-50, 1991.
-
(1991)
Blood l78
, pp. 44-50
-
-
Salmon, S.E.1
Dalton, W.S.2
Grogan, T.M.3
-
32
-
-
18044368633
-
Genomic changes identified by comparative genomic hybridisation in docetaxel-resistant breast cancer cell lines
-
McDonald SL, Stevenson DA, Moir SE, et al. Genomic changes identified by comparative genomic hybridisation in docetaxel-resistant breast cancer cell lines. Eur J Cancer 41: 1086-94, 2005.
-
(2005)
Eur J Cancer
, vol.41
, pp. 1086-1094
-
-
McDonald, S.L.1
Stevenson, D.A.2
Moir, S.E.3
-
33
-
-
33746455616
-
Chemopreventive efficacy of all-trans-retinoic acid in biodegradable microspheres against epithelial cancers: Results in a 4-nitroquinoline 1-oxide-induced oral carcinogenesis model
-
Choi Y, Kim SY, Park K, et al. Chemopreventive efficacy of all-trans-retinoic acid in biodegradable microspheres against epithelial cancers: Results in a 4-nitroquinoline 1-oxide-induced oral carcinogenesis model. Int J Pharm 320: 45-52, 2006.
-
(2006)
Int J Pharm
, vol.320
, pp. 45-52
-
-
Choi, Y.1
Kim, S.Y.2
Park, K.3
-
34
-
-
34548237309
-
Pathways to tamoxifen resistance
-
Riggins RB, Schrecengost RS, Guerrero MS, Bouton AH. Pathways to tamoxifen resistance. Cancer Lett 256: 1-24, 2007.
-
(2007)
Cancer Lett
, vol.256
, pp. 1-24
-
-
Riggins, R.B.1
Schrecengost, R.S.2
Guerrero, M.S.3
Bouton, A.H.4
-
35
-
-
0000216613
-
Chemotherapeutic synergism, potentiation and antagonism
-
Dulbecco R, editor., 2nd edn. San Diego, Academic Press
-
Chou T-C, Rideout D, Chou JH, Bertino JR. Chemotherapeutic synergism, potentiation and antagonism. In: Dulbecco R, editor. Encyclopedia of human biology (vol 2), 2nd edn. San Diego, Academic Press. 1997, pp 675-83.
-
(1997)
Encyclopedia of human biology
, vol.2
, pp. 675-683
-
-
Chou, T.-C.1
Rideout, D.2
Chou, J.H.3
Bertino, J.R.4
-
36
-
-
33750293878
-
Randomized study of paclitaxel and tamoxifen deposition into human brain tumors: Implications for the treatment of metastatic brain tumors
-
Fine RL, Chen J, Balmaceda C, et al. Randomized study of paclitaxel and tamoxifen deposition into human brain tumors: Implications for the treatment of metastatic brain tumors. Clin Cancer Res 12: 5770-6, 2006.
-
(2006)
Clin Cancer Res
, vol.12
, pp. 5770-5776
-
-
Fine, R.L.1
Chen, J.2
Balmaceda, C.3
|